Atara Biotherapeutics, Inc. (ATRA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 516K | 1.59M | 3.45M | 17.57M | 98.15M | 32.75M | 40.19M | 28.64M | 27.36M | 4.25M | 2.14M | 957K |
| Revenue Growth % | -99.47% | -95.13% | -91.41% | -38.63% | 258.77% | 670.3% | 1779.79% | 2892.69% | 2131.4% | 1823.98% | -52.05% | -98.14% |
| Cost of Goods Sold | 124K | 104K | 115K | 554K | 20.44M | 6.79M | 7.6M | 4.63M | 1.99M | 3.16M | 2.62M | 2.9M |
| COGS % of Revenue | 24.03% | 6.52% | 3.33% | 3.15% | 20.82% | 20.75% | 18.92% | 16.16% | 7.26% | 74.32% | 122.31% | 302.51% |
| Gross Profit | 392K | 1.49M | 3.34M | 17.02M | 77.71M | 25.96M | 32.59M | 24.01M | 25.37M | 1.09M | -477K | -1.94M |
| Gross Margin % | 75.97% | 93.48% | 96.67% | 96.85% | 79.18% | 79.25% | 81.08% | 83.84% | 92.74% | 25.68% | -22.31% | -202.51% |
| Gross Profit Growth % | -99.5% | -94.26% | -89.76% | -29.12% | 206.28% | 2277.11% | 6931.87% | 1339.06% | 2412.08% | 101.83% | -110.7% | -103.76% |
| Operating Expenses | 3.76M | 4.05M | 6.91M | 13.82M | 38.91M | 38.16M | 54.34M | 42.24M | 56.62M | 54.37M | 69.14M | 69.48M |
| OpEx % of Revenue | 728.88% | 254.17% | 200.17% | 78.66% | 39.64% | 116.51% | 135.22% | 147.5% | 206.96% | 1278.67% | 3233.63% | 7259.77% |
| Selling, General & Admin | 3.6M | 4.28M | 3.99M | 5.93M | 11.47M | 9.44M | 10.42M | 8.91M | 11.11M | 10.39M | 12.25M | 13.34M |
| SG&A % of Revenue | 697.09% | 268.15% | 115.46% | 33.77% | 11.69% | 28.82% | 25.93% | 31.12% | 40.62% | 244.31% | 572.83% | 1393.42% |
| Research & Development | 164K | -223K | 2.92M | 7.31M | 27.43M | 28.72M | 43.92M | 33.33M | 45.51M | 43.98M | 56.89M | 56.14M |
| R&D % of Revenue | 31.78% | -13.98% | 84.71% | 41.59% | 27.95% | 87.69% | 109.29% | 116.38% | 166.34% | 1034.36% | 2660.8% | 5866.35% |
| Other Operating Expenses | 0 | 0 | 0 | 579K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.37M | -2.56M | -3.57M | 3.2M | 38.8M | -12.2M | -21.76M | -18.23M | -31.25M | -53.28M | -69.61M | -71.41M |
| Operating Margin % | -652.91% | -160.69% | -103.5% | 18.19% | 39.53% | -37.26% | -54.14% | -63.66% | -114.22% | -1252.99% | -3255.94% | -7462.28% |
| Operating Income Growth % | -108.68% | 79% | 83.57% | 117.54% | 224.18% | 77.1% | 68.75% | 74.47% | 58.35% | 29.47% | 17.74% | -122.25% |
| EBITDA | -3.34M | -2.51M | -3.54M | 3.43M | 40.6M | -11.1M | -20.53M | -16.9M | -29.86M | -52.07M | -68.4M | -70.21M |
| EBITDA Margin % | -647.29% | -157.62% | -102.46% | 19.53% | 41.36% | -33.9% | -51.07% | -59.01% | -109.13% | -1224.65% | -3199.39% | -7336.78% |
| EBITDA Growth % | -108.23% | 77.36% | 82.76% | 120.31% | 235.98% | 78.68% | 69.99% | 75.93% | 59.55% | 29.9% | 17.84% | -128.75% |
| D&A (Non-Cash Add-back) | 29K | 49K | 36K | 236K | 1.79M | 1.1M | 1.23M | 1.33M | 1.39M | 1.21M | 1.21M | 1.2M |
| EBIT | -3.37M | -2.51M | -3.37M | 3.36M | 39.03M | -11.7M | -20.74M | -17.79M | -30.57M | -59.26M | -68.42M | -69.73M |
| Net Interest Income | -776K | -794K | -705K | -829K | -781K | -420K | -724K | -812K | -549K | -465K | -177K | 317K |
| Interest Income | 54K | 100K | 204K | 143K | 236K | 597K | 459K | 450K | 604K | 711K | 1.22M | 1.7M |
| Interest Expense | 830K | 894K | 909K | 972K | 1.02M | 1.02M | 1.18M | 1.26M | 1.15M | 1.18M | 1.4M | 1.38M |
| Other Income/Expense | -776K | -843K | -701K | -807K | -792K | -509K | -169K | -818K | -481K | -7.16M | -204K | 307K |
| Pretax Income | -4.14M | -3.41M | -4.28M | 2.39M | 38.01M | -12.71M | -21.93M | -19.05M | -31.73M | -60.44M | -69.82M | -71.11M |
| Pretax Margin % | -803.29% | -213.54% | -123.81% | 13.6% | 38.73% | -38.81% | -54.56% | -66.51% | -115.98% | -1421.43% | -3265.48% | -7430.2% |
| Income Tax | 0 | 0 | 28K | 3K | 0 | -19K | -17K | 0 | 24K | 11K | -19K | 1K |
| Effective Tax Rate % | 0% | 0% | -0.65% | 0.13% | 0% | 0.15% | 0.08% | 0% | -0.08% | -0.02% | 0.03% | -0% |
| Net Income | -4.14M | -3.41M | -4.3M | 2.39M | 38.01M | -12.69M | -21.91M | -19.05M | -31.75M | -60.45M | -69.8M | -71.11M |
| Net Margin % | -803.29% | -213.54% | -124.62% | 13.58% | 38.73% | -38.75% | -54.51% | -66.51% | -116.07% | -1421.68% | -3264.59% | -7430.3% |
| Net Income Growth % | -110.91% | 73.17% | 80.36% | 112.53% | 219.71% | 79% | 68.61% | 73.21% | 57.53% | 18.94% | 17% | -485.08% |
| Net Income (Continuing) | -4.14M | -3.41M | -4.3M | 2.39M | 38.01M | -12.69M | -21.91M | -19.05M | -31.75M | -60.45M | -69.8M | -71.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.29 | -0.25 | -0.32 | 0.19 | 3.50 | -1.19 | -2.93 | -3.10 | -5.65 | -13.98 | -16.40 | -16.91 |
| EPS Growth % | -108.29% | 78.99% | 89.08% | 106.13% | 161.99% | 91.49% | 82.13% | 81.67% | 68.6% | 22.63% | 20.12% | -475.78% |
| EPS (Basic) | -0.29 | -0.25 | -0.32 | 0.20 | 3.53 | -1.19 | -2.93 | -3.10 | -5.65 | -13.98 | -16.40 | -16.91 |
| Diluted Shares Outstanding | 14.08M | 12.72M | 13.56M | 12.31M | 10.85M | 10.69M | 7.47M | 6.14M | 5.62M | 4.33M | 4.26M | 4.2M |
| Basic Shares Outstanding | 14.08M | 12.54M | 13.56M | 12.2M | 10.76M | 10.69M | 7.47M | 6.14M | 5.62M | 4.33M | 4.26M | 4.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |